AHA ACC cholesterol guidelines and testing

an you pl give me clickable links for all of them ? - 2018/2019 AHA/ACC/Multisociety Cholesterol & Primary Prevention Guidelines: list South Asian ancestry as a “risk enhancer,” support ApoB and Lp(a) testing, and CAC to refine statin decisions. J Am Coll Cardiol 2019;73:e285–e350; Circulation 2019;140:e596–e646. 2022 ACC Expert Consensus Decision Pathway on nonstatin therapies: endorses ApoB and Lp(a) to refine risk and therapy. J Am Coll Cardiol 2022;80:1366–1418. 2023 AHA Scientific Statement on Lp(a): recommends one-time Lp(a) testing, especially in high-risk groups including South Asians. Circulation 2023;148:e282–e294. 2022 European (ESC/EAS) Dyslipidemia Guidelines: support ApoB, Lp(a), CAC for risk refinement; ApoB as a primary target when trigly …Read more

Here you go—direct links to each guideline/statement: - 2018/2019 AHA/ACC/Multisociety Cholesterol Guideline (JACC 2019;73:e285–e350) - 2019 ACC/AHA Primary Prevention Guideline (Circulation 2019;140:e596–e646) - 2022 ACC Expert Consensus Decision Pathway on Nonstatin Therapies (JACC 2022;80:1366–1418) - 2023 AHA Scientific Statement on Lipoprotein(a) (Circulation 2023;148:e282–e294) - 2023 AHA/ACC/Multisociety Guideline for Chronic Coronary Disease (has Lp(a)/ApoB context) - 2021 ESC/EAS Dyslipidaemia Guidelines (latest European; supports ApoB/Lp(a)/CAC; supersedes 2019/2022 drafts) - ESC/EAS Pocket Guideline PDF Note: The “2022 European” update you mentioned is encompassed by the 2021 ESC/EAS full guideline and subsequent focused updates/position papers. This is educational information only.

Ask BHAI about thisLink copied
Browse all 334 FAQs →